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Since the introduction of the da Vinci surgical system 
(Intuitive Surgical, Sunnyvale, CA, USA), the trend of 
minimally invasive surgery has accelerated. Recently, 
Intuitive Surgical launched the new da Vinci Xi platform 
and a prototype of  a single-port surgical system. Other 
platforms from other robotic companies are on the horizon. 
The multiport surgical robotic ALF-X system (SORAR 
SpA, Milan, Italy) was initially introduced for gynecological 
surgery and was recently assessed in a preclinical animal 
study of robot-assisted partial nephrectomy (RPN) [1,2]. The 
ALF-X robot consists of  a remote-controlled unit with a 
haptic handle, a three-dimensional high-definition monitor, 
an infrared eye-tracking system, and four detached robotic 
arms. The haptic feedback allows the surgeon to feel the 
force and resistance to the tissue. The surgeon can move 
the camera by gaze, and the system includes a large set of 
reusable instruments.
Other manufacturers include Medrobotics (Raynham, 
MA, USA), which received U.S. Food and Drug Admini-
stration clearance for the Flex Robotic System in July 
2015. The Flex Robotic System provides surgeons with 
single-site access visualization of hard-to-reach anatomical 
locations. Titan Medical (Toronto, ON, Canada) is a public 
company based on Single Port Orifice Robotic Technology. 
The system utilizes a 25-mm single-access port that contains 
two articulating instruments and a three-dimensional high-
definition camera. The Korean domestic manufacturer 
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Meree Company has developed the REVO I robot system. 
A clinical trial for the REVO I robot has been planned to 
supplement the global market. 
Meanwhile, the Korean national evidence-based health 
care collaborating agency (NECA) published a preliminary 
report on the clinical feasibility and cost-effectiveness of 
robot-assisted radical prostatectomy (RARP) from a total 
of five high-volume centers to provide fundamental data 
for instituting the national health policy. Concerning 
oncological outcomes, there were no significant differences 
in biochemical recurrence or the positive surgical margin 
rate. Concerning functional outcomes, RARP revealed the 
highest continence rate of 88.7% and 95.3% achievement of 
complete continence at postoperative 3 months and 3 years, 
respectively. 
Concerning cost analysis of the robotic system, with a 
threshold value of 30.5 million Korean won (KRW; 27,000 
US dollars [USD]), a cost-effectiveness analysis of purchase 
among RARP, laparoscopic radical prostatectomy, and open 
radical prostatectomy (ORP) showed that RARP was not yet 
cost-effective. RARP could be cost-effective if the expenses 
could be reduced by 8.3 million KRW (7,400 USD). The 
effectiveness of the system could not offset the costs, because 
there was no significant difference in effectiveness among 
the different procedures, and the robotic cost of  RARP 
was significantly more than that of the other procedures. 
However, owing to the short term of 1 year of data used for 
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the cost-effectiveness analysis, long-term prospective study is 
necessary for further high-quality analysis. 
Recently, high-quality evidence is emerging comparing 
robotics with its traditional counterparts. In a study of 
RARP, Wallerstedt et al. [3] performed a prospective 
comparative trial of ORP versus RARP in a Swedish group 
of 14 centers including a total of 2,506 patients. The study 
was conducted prospectively over a 3-year period with 
patient-reported outcome measurement. The RARP group 
had less perioperative bleeding and shorter hospital stays. 
Reoperation during the hospital stay and seeking health 
care for cardiovascular reasons were more frequent after 
ORP. Haglind et al. [4] performed a prospective, controlled, 
nonrandomized trial evaluating urinary incontinence and 
erectile dysfunction in a total of  14 centers in Sweden 
including 2,625 patients and concluded that RARP was 
beneficial in preserving erectile function compared with 
ORP, with no statistically signif icant dif ferences in 
continence or surgical margins. 
In an analysis of  RPN, Choi et al. [5] performed a 
systematic review and meta-analysis of 23 studies and 2,240 
patients. The authors concluded that RPN is more favorable 
than laparoscopic partial nephrectomy (LPN) in terms 
of a lower conversion rate to radical nephrectomy, more 
favorable renal function, a shorter length of hospital stay, 
and a shorter warm ischemia time. Potretzke and Bhayani [6] 
wrote an editorial comment on our previous article [5]. The 
authors mentioned the superior outcomes of RPN and the 
efficiency of excision and suturing. The true value of RPN 
is in its feasibility, accessibility, and learning curves, and the 
procedure competing with RPN now is not LPN, but rather 
radical nephrectomy, ablation, and observation.
There will be more new robotic platforms, and new 
prospective randomized data will become available. The 
Korean Journal of Urology hopes to continue to share this 
knowledge on recent updates in robotic minimally invasive 
surgery and to enhance future perspectives on robotic 
minimally invasive surgery.
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